Lilly triples U.S. demand as oral obesity drug challenges Wegovy
Eli Lilly's obesity drug Paoundayo reported $184M in Q3 sales, up 88% from Q2 but below forecasts. Lilly attributes the shortfall to initial inventory sales and highlights a 3x increase in U.S. demand. Paoundayo faces stiff competition from Novo Nordisk's Wegovy, which has a 75% market share. Lilly's total Q3 sales rose 39% YoY to $24.397B, with Mounjaro and zepbound driving growth.
How this was made
The 30-second read
Why it matters
The Q3 sales miss may trigger short‑term price pressure, but the tripling of U.S. demand signals strong growth trajectory.
Market read
First‑report Q3 earnings data for Lilly's obesity drug provides actionable insight for pharma and biotech traders.
What to watch
Potential upcoming FDA decision for a type‑2 diabetes indication could drive future upside.
Background
Eli Lilly's oral GLP‑1 obesity drug Paoundayo competes with Novo Nordisk's Wegovy pill; the market is shifting toward oral formulations.
Ticker impact
Eli Lilly reported Q3 sales of its oral obesity drug Paoundayo at $184M, noting U.S. demand more than tripled quarter‑over‑quarter.
likely modest downside as market prices in the inventory‑adjusted shortfall, though long‑term upside from demand growth.
The article provides first‑report Q3 numbers and demand metrics, a material update for a large‑cap pharma.
Market effects
Highlights accelerating adoption of oral GLP‑1 obesity treatments, pressuring peers like Novo Nordisk.
U.S. obesity‑drug market sees rapid growth, potentially boosting related biotech stocks.
European regulators reviewing approvals could expand market size globally.
Counterpoint
Inventory inclusion may mask true demand; investors could view the miss as a red flag.
Key entities
- CompanyEli Lilly and Company
Pharmaceutical firm launching oral obesity treatment Paoundayo.
- CompanyNovo Nordisk
Competitor with Wegovy oral GLP‑1 product.
